AI, pancreatic cancer and food intolerance headline wide range of Cellvizio abstracts at gastroenterology’s largest international meeting <\/i><\/b><\/p>\n
Paris and Boston, May 6, 2024 – 5:45 p.m. CEST – Mauna Kea Technologies <\/b>(Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p\/nCLE) platform, today announced the presentation of 9 abstracts supporting Cellvizio® at the Digestive Disease Week® (DDW) Conference, being held on May 18-21, 2024 in Washington, DC. These abstracts focus on artificial intelligence, pancreatic cystic lesions and pancreatic cancer, food intolerance and other gastrointestinal disorders. Studies and presentations are focused on how the use of Cellvizio® positively impacts patient management and outcomes. <\/p>\n
Members of the Mauna Kea executive team will be present at DDW and meeting with physicians, industry partners, and societies, and welcome the opportunity to discuss the Company’s recent achievements and future opportunities as announced in the recent FY 2023 & Q1 2024 sales press release. <\/p>\n
"Each year, DDW brings the entire gastroenterology healthcare community together, and we are proud to have such a wide range of independent scientific abstracts and data about Cellvizio on display, especially in the rapidly developing field of artificial intelligence,” <\/i>said Sacha Loiseau, Ph.D., Chairman and Chief Executive Officer of Mauna Kea Technologies. <\/b>“Cellvizio's role in the classification and risk stratification of pancreatic cysts advances the outlook for the management of patients at risk of pancreatic cancer. Moreover, our clinical value in food intolerance identification and management is maturing quickly, setting up the next big opportunity for Cellvizio.” <\/i><\/p>\n
Highlighted featured presentations: <\/u><\/p>\n